Kmsmith,You are correct that this will not be an easy job and...

Kmsmith,

You are correct that this will not be an easy job and its a big leap from the current market cap to the levels that may be expected in a formal partnership with big pharma.

However I don't believe the board would even look at a 5x takeover. Paul Hopper as the chair is very well connected with us financing and medical companies, and amongst others Dr Leonard Post was on the board of Biovex when it had the deal with Amgen so must know how to value Viralytics. Also the CEO is new in the job, wants to develop his career further and I can't believe he would sell out for a low offer.

That's my hope anyway,

Cheers